Latest Licensing Deals News

BrainChip Holdings has signed a global IP license agreement with ASICLAND, enabling integration of its Akida neuromorphic AI technology into custom SoC designs with a royalty-based revenue model.

Dimerix has completed adult patient recruitment in its Phase 3 ACTION3 trial for DMX-200, with a blinded review confirming the study remains statistically powered to demonstrate treatment efficacy. The company also appointed a new CFO and is negotiating up to US$50 million in non-dilutive funding.

Algorae Pharmaceuticals strengthened its balance sheet with $5.47 million cash reserves and broadened its commercial footprint through new licensing deals and AI-driven drug validation.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.

ION Video Ltd has responded to ASX inquiries by confirming its recent discussions with Meta Platforms and Alphabet remain preliminary, with no binding agreements or commercial terms agreed. The company emphasised that the engagements are exploratory and non-binding, explaining why earlier disclosure was not required.

ION Video has entered substantive early-stage discussions with Meta and Alphabet, exploring potential applications of its patented video virtualization technology. These talks are part of a broader engagement with major global tech players, though no formal deals have yet been struck.

Audeara Ltd has posted its second straight quarter of positive operating cash flow, driven by a record Australian wholesale order and expanding technology licensing deals. The company’s cash balance rose to $1.05 million as it advances global market expansions.

BrainChip Holdings has inked a global licensing agreement with Korea’s EDGEAI, granting access to its Akida 2 neuromorphic AI technology for EDGEAI’s upcoming semiconductor products. The deal includes milestone payments and royalties, marking a significant step in BrainChip’s global expansion and the growing edge AI market.

Temas Resources has formed a Scientific Advisory Board of hydrometallurgical leaders to accelerate the rollout of its innovative Regenerative Chloride Leaching technology, promising major cost and environmental benefits in critical minerals processing.

Eve Health Group is advancing its proprietary reformulation platform with two fast-onset products launched under Australia's SAS-B pathway, targeting large underserved markets in women's and men's health. The company’s capital-light, partner-led model aims for rapid revenue growth post-ARTG registration.

Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.